Quadrivalent human papillomavirus (HPV) vaccination can substantially reduce the risk of invasive cervical cancer, by up to almost 90 percent in women who were vaccinated early, a large Swedish registry-based study has shown.
Initial active treatment is associated with generally worse long-term self-reported quality of life (QoL) in men with localized prostate cancer compared with those without a diagnosis of the disease, according to a study. Furthermore, radical prostatectomy results in some adverse effects, particularly in relation to sexual outcomes.
Olaparib, a PARP* inhibitor used to treat ovarian and breast cancer, also extends overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC) harbouring at least one mutation in BRCA1, BRCA2, or ATM, according to final report of the PROfound** study presented at ESMO 2020.
The highly specific MET inhibitor capmatinib may be a new therapeutic option for patients with MET exon 14-mutated or MET-amplified non-small-cell lung cancer (NSCLC), the phase II GEOMETRY mono-1 study has shown.
Treatment with tipifarnib appears to be safe with favourable efficacy in patients with treatment-refractory urothelial carcinoma harbouring HRAS mutations, according to the results of a phase II trial.
A community initiative targeted at metastatic breast cancer (mBC) patients has recently been launched by the Breast Cancer Welfare Association Malaysia (BCWA). Called #UnPause, the initiative aims to rally mBC patients to live their lives to the fullest. It further aims to raise awareness of mBC among the public and prevent treatment disruption as a result of the COVID-19 pandemic. #UnPause is also supported by Pfizer.
Well-differentiated appendiceal neuroendocrine neoplasms is a low-malignant disease, and performing prophylactic surgery should be reconsidered given that the procedure subjects patients to excessive surgery, affects functional health-related quality of life, and increases the risk of diarrhoea, according to a study.
Inflammatory indices, such as the neutrophil-to-lymphocyte (NLR) and lymphocyte-to-monocyte (LMR) ratios, may help determine the efficacy of atezolizumab monotherapy in patients with nonsmall cell lung cancer (NSCLC), a recent study has found.
Durvalumab with or without tremelimumab in the first-line setting does not improve overall survival (OS) over standard-of-care (SoC) chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma, according to the phase III DANUBE trial.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.